Literature DB >> 30917983

Results from a Prospective In Vitro Study on the Mecillinam (Amdinocillin) Susceptibility of Enterobacterales.

Frieder Fuchs1, Axel Hamprecht2,3.   

Abstract

The activity of mecillinam (amdinocillin) was assessed in Enterobacterales (n = 420) isolated from urine samples between 2016 and 2017. Mecillinam susceptibilities were 97.4% in Escherichia coli isolates (294/302), 89.7% in Klebsiella spp. isolates (52/58), and 93.3% in Proteus mirabilis isolates (28/30). Among extended-spectrum β-lactamase (ESBL) producers, 95.2% (99/104) were mecillinam susceptible, including two OXA-48-producing Klebsiella pneumoniae isolates. In Enterobacter spp. and Citrobacter spp., MICs were low (MIC50 = 0.5 mg/liter). In conclusion, the activity of mecillinam was high in Enterobacterales, even among multidrug-resistant isolates.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  ESBL; Enterobacteriaceaezzm321990; OXA-48; UTI; mecillinam; multidrug resistance; pivmecillinam; urinary tract infection

Mesh：

Substances：

Year:  2019        PMID： 30917983      PMCID： PMC6437539          DOI： 10.1128/AAC.02402-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Use of an Enrichment Broth Improves Detection of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae in Clinical Stool Samples.

Authors:  Nathalie Jazmati; Rebecca Hein; Axel Hamprecht
Journal:  J Clin Microbiol       Date:  2015-11-25       Impact factor: 5.948

2.  In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase.

Authors:  Emma C L Marrs; Kathryn M Day; John D Perry
Journal:  J Antimicrob Chemother       Date:  2014-06-10       Impact factor: 5.790

Review 3.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options.

Authors:  Ana L Flores-Mireles; Jennifer N Walker; Michael Caparon; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2015-04-08       Impact factor: 60.633

4.  Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.

Authors:  N T Mutters; S Zimmermann; M Kaase; A Mischnik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-03       Impact factor: 3.267

5.  Multiplex Immunochromatographic Detection of OXA-48, KPC, and NDM Carbapenemases: Impact of Inoculum, Antibiotics, and Agar.

Authors:  Ahmad Saleh; Stephan Göttig; Axel G Hamprecht
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

Review 6.  [Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients : Update 2017 of the interdisciplinary AWMF S3 guideline].

Authors:  J Kranz; S Schmidt; C Lebert; L Schneidewind; W Vahlensieck; U Sester; R Fünfstück; S Helbig; W Hofmann; E Hummers; M Kunze; E Kniehl; K Naber; F Mandraka; B Mündner-Hensen; G Schmiemann; F M E Wagenlehner
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639

Review 7.  Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria.

Authors:  Simon Dewar; Lee C Reed; Roland J Koerner
Journal:  J Antimicrob Chemother       Date:  2013-09-25       Impact factor: 5.790

8.  The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.

Authors:  Gian Carlo Schito; Kurt G Naber; Henry Botto; Juan Palou; Teresita Mazzei; Laura Gualco; Anna Marchese
Journal:  Int J Antimicrob Agents       Date:  2009-06-07       Impact factor: 5.283

9.  Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women.

Authors:  Tor J Monsen; Stig E Holm; Björn Magnus Ferry; Sven A Ferry
Journal:  APMIS       Date:  2014-04       Impact factor: 3.205

10.  Rapid detection of NDM, KPC and OXA-48 carbapenemases directly from positive blood cultures using a new multiplex immunochromatographic assay.

Authors:  Axel Hamprecht; Jörg Janne Vehreschild; Harald Seifert; Ahmad Saleh
Journal:  PLoS One       Date:  2018-09-14       Impact factor: 3.240
View more
  6 in total

1.  In Vivo Evolution of CTX-M-215, a Novel Narrow-Spectrum β-Lactamase in an Escherichia coli Clinical Isolate Conferring Resistance to Mecillinam.

Authors:  Minggui Wang; Qinglan Guo; Mengyun Yin; Guoping Hu; Zhen Shen; Chengli Fang; Xuefei Zhang; Dan Li; Yohei Doi; Yu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

2.  Activity of mecillinam against carbapenem-resistant Enterobacterales.

Authors:  Cécile Emeraud; Alexandre Godmer; Delphine Girlich; Océane Vanparis; Fériel Mahamdi; Elodie Creton; Agnès B Jousset; Thierry Naas; Rémy A Bonnin; Laurent Dortet
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

3.  Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20.

Authors:  Michael Kresken; Yvonne Pfeifer; Florian Wagenlehner; Guido Werner; Esther Wohlfarth; On Behalf Of Study Group 'Antimicrobial Resistance' Of The Paul Ehrlich Society For Infection Therapy
Journal:  Antibiotics (Basel)       Date:  2022-05-31

4.  In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales.

Authors:  Lars Plambeck; Frieder Fuchs; Janko Sattler; Axel Hamprecht
Journal:  JAC Antimicrob Resist       Date:  2022-06-16

5.  Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam.

Authors:  Frieder Fuchs; Aysel Ahmadzada; Lars Plambeck; Thorsten Wille; Axel Hamprecht
Journal:  Front Microbiol       Date:  2021-01-12       Impact factor: 5.640

6.  US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales.

Authors:  Thomas P Lodise; Anne Santerre Henriksen; Thomas Hadley; Nimish Patel
Journal:  Open Forum Infect Dis       Date:  2021-10-15       Impact factor: 3.835
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.